Tarsus reported Q3 XTENVI net product sales of $194.6 million and raised full-year 2026 sales guidance to $715 million to $730 million. DTC spending will increase to approximately $95 million.
TARS · Tarsus Pharmaceuticals, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Tarsus Pharmaceuticals reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64%, but a $668.3 million net loss including $632.2 million of acquired in-process research and development expense.
Tarsus reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64% year-over-year. Net loss widened to $668.3 million, driven by $632.2 million of acquired in-process R&D from the iRenix and Alkeus acquisitions. Cash, cash equivalents and marketable securities were $309.6 million as of September 30, 2026.
Tarsus Pharmaceuticals, Inc. registered up to 2,908,692 shares of common stock for resale by selling stockholders; it will receive no proceeds from their sales.
Tarsus Pharmaceuticals, Inc. registered up to 2,232,144 shares of common stock for resale by selling stockholders, comprising 2,098,519 shares and 133,625 shares issuable upon exercise of pre-funded warrants. The company will receive no proceeds from share sales.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 3, 2026TL;DR. XDEMVY delivered record sales of $194.6 million, up approximately 64% year over year, with approximately 93% gross margin, and management raised 2026 sales guidance to $715 million–$730 million amid broad commercial momentum. Tarsus advanced its pipeline and completed two acquisitions, but reported a $668.3 million net loss, increased R&D and SG&A expenses, material development costs, and deferred TP-03 filings in Europe and Japan.
- + Management raised full-year 2026 XDEMVY sales guidance to $715 million to $730 million.
- + Commercial momentum was supported by broader ECP prescribing, stronger patient acquisition, and increasing retreatment.
- + XDEMVY has surpassed one million bottles dispensed and $1 billion in cumulative net product sales since launch.
- + The pipeline advanced multiple clinical milestones across TP-04, TP-05, IRX-101, and gildeuretinol.
- − Tarsus reported a Q3 net loss of $668.3 million, compared with $12.6 million in the prior-year period.
- − Management guides to full-year SG&A expense of $605 million to $620 million, with DTC investment increasing by $5 million to approximately $95 million.
- − Tarsus deferred TP-03 regulatory filings in Europe and Japan because of most favored nation regulations.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| net product sales | $194.57M | FY2026 Q3 | +63.9% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TARS
this stock
Tarsus Pharmaceuticals, Inc.
|
$3.86B | -4.5% | +146.7% | — | 12.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$135.44B | +17.8% | +46.2% | 34.4 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$99.08B | +24.1% | +20.8% | 21.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.68B | +601.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$64.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 3, 2026
- This year
- 30
Tarsus Pharmaceuticals reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64%, but a $668.3 million net loss including $632.2 million of acquired in-process research and development expense.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TARS | +5.9% | +10.1% | +31.3% | +4.5% | -4.5% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | +8.3% | +14.9% | +34.3% | +7.6% | -11.9% |